Neoleukin Therapeutics, Inc.·4

May 4, 4:35 PM ET

Patel Priti 4

4 · Neoleukin Therapeutics, Inc. · Filed May 4, 2021

Insider Transaction Report

Form 4
Period: 2021-04-30
Patel Priti
Chief Medical Officer
Transactions
  • Award

    Restricted Stock Units

    2021-04-30+20,00020,000 total
    Exercise: $0.00Common Stock (20,000 underlying)
  • Award

    Stock Option (Right to Buy)

    2021-04-30+475,000475,000 total
    Exercise: $12.49Exp: 2031-04-30Common Stock (475,000 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
  • [F2]The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
  • [F3]The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.
  • [F4]The option vests as to 1/4 of the total shares on April 30, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION